All Things Newz

Novartis says lung cancer drug canakinumab failed phase III trial


Article content

ZURICH — Novartis said on Monday its canakinumab drug to help treat non-small cell lung cancer failed a phase III trial.

The drug, used as an adjuvant treatment, did not meet its primary endpoint of disease-free survival, the Swiss company said. (Reporting by John Revill; Editing by Christian Schmollinger)


Source link

Related posts

Oil jumps on Russia supply jitters, lower dollar

Nearly 100 Grassroots Abortion Funds Face Rising Post-Roe Need

Asia shares dip on hawkish Fed remarks; commods rise on China reopening